D.E. Shaw & Co
RYTM icon

D.E. Shaw & Co’s Rhythm Pharmaceuticals RYTM Stock Holding History

D.E. Shaw & Co’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-50,000
Closed -$1.23M – 5085
2022
Q3 		$1.23M Buy
+50,000
New +$930K ﹤0.01% 3439

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

D.E. Shaw & Co's RYTM Position: Q1 2026 in Review

D.E. Shaw & Co increased its Rhythm Pharmaceuticals (RYTM) stake by 4.1% in Q1 2026, buying an estimated $126K and bringing the position to 32,652 shares worth $2.84M. The position accounts for ﹤0.01% of the portfolio, ranked #2638.

D.E. Shaw & Co first reported a position in RYTM in Q2 2018 and has held it in 18 quarters since. The position peaked at $10.4M in Q4 2022. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.

  • D.E. Shaw & Co held 32,652 shares of Rhythm Pharmaceuticals worth $2.84M as of Q1 2026.
  • D.E. Shaw & Co bought 1,296 Rhythm Pharmaceuticals shares in Q1 2026, an estimated $126K.
  • Rhythm Pharmaceuticals made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #2638 holding.
  • D.E. Shaw & Co first reported a position in Rhythm Pharmaceuticals in Q2 2018 and has held it in 18 quarters since.
  • D.E. Shaw & Co's Rhythm Pharmaceuticals position peaked at $10.4M in Q4 2022.
  • 285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.